Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meglumine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 13/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | STAT5B | P51692 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meglumine SCHEMBL2853649 | 0.89 | STAT3 (0.45) | STAT3PTPN11PTPRO | |
| SCHEMBL2855309 | 0.86 | CNR2 (0.55) | CNR2STAT3STAT1STAT5BPTPN11 | |
| Meglumine SCHEMBL4454874 | 0.84 | STAT3 (0.46) | STAT3PTPN11PTPRO | |
| Meglumine SCHEMBL4452475 | 0.83 | STAT3 (0.57) | STAT3 | |
| Meglumine SCHEMBL4458998 | 0.82 | STAT3 (0.47) | STAT3PTPN11PTPRO | |
| SCHEMBL13711715 | 0.78 | CNR2 (0.58) | CNR2STAT3STAT1STAT5BNR1H4 | |
| SCHEMBL1734576 | 0.77 | PTPN11 (0.62) | CNR2STAT3PTPN11PTPRONR1H4 | |
| Meglumine SCHEMBL2852826 | 0.75 | STAT3 (0.47) | STAT3STAT5B | |
| SCHEMBL2855112 | 0.74 | STAT3 (0.57) | STAT3PTPN11PTPRO | |
| SCHEMBL2851611 | 0.73 | STAT3 (0.49) | STAT3STAT1STAT5BPTPN11PTPRO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105913-A1 | Alkynyl aryl carboxamides | ECHS1, IRS1, HCCS | CNR2 198/4885STAT3 2684/4885STAT1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.